Pharmacokinetic Profile of Ganciclovir After its Oral Administration and From its Prodrug, Valganciclovir, in Solid Organ Transplant Recipients

Author： Wiltshire Hugh  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.44, Iss.5, 2005-01, pp. : 495-507

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Valganciclovir in Adult Solid Organ Transplant Recipients: Pharmacokinetic and Pharmacodynamic Characteristics and Clinical Interpretation of Plasma Concentration Measurements

By Perrottet Nancy  

Clinical Pharmacokinetics, Vol. 48, Iss. 6, 2009-06 ,pp. : 399-418

Adis International

Access to resources Recommend Favorite

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients

By Yu Marie A   Park Jeong M  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 807-815

Informa Healthcare

Access to resources Recommend Favorite

Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients

By Åsberg Anders   Rollag Halvor   Hartmann Anders  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1159-1166

Informa Healthcare

Access to resources Recommend Favorite

Ganciclovir: An Update of its Use in the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients

By McGavin J.K.   Goa K.L.  

Drugs, Vol. 61, Iss. 8, 2001-01 ,pp. : 1153-1183

Adis International

Access to resources Recommend Favorite

Ganciclovir: An Update of its Use in the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients

By Noble S.   Faulds D.  

Drugs, Vol. 56, Iss. 1, 1998-07 ,pp. : 115-146

Adis International

Access to resources Recommend Favorite